DelSiTech Forms Research Collaboration With Orion

DelSiTech has signed a collaboration agreement with Orion Corporation. The agreement enables Orion to apply DelSiTech drug delivery technology in combination with its drug molecules for different therapeutic purposes.

Reportedly, DelSiTech will receive fully allocated payments for project work and also milestone payments tied to the progress of possible development projects. The agreement also contains an option for licensing and further collaboration.

Harry Jalonen, CEO of DelSiTech, said: “We are proud to have been chosen by Orion as a partner for the development of new innovative drug delivery products. This agreement opens possibilities for the DelSiTech drug delivery technology in new interesting fields. An important advantage is also that Orion’s R&D centre in Turku is located close to the site of DelSiTech.”

Antti Haapalinna, vice president of Research at Orion, said: “We are happy to partner with DelSiTech and start research collaboration on the possible applications of this interesting delivery technology. In Orion, this kind of activity represents strategic research partnership, in which the parties join their knowledge to develop new medicines with added therapeutic value.”